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Web-Based Assessment of
Parkinson’s Prodromal Markers
Identifies GBA Variants
Identifying those “at risk” of Parkinson’s disease (PD) is a
priority and a key strategy for testing neuroprotective
agents.1 PREDICT-PD is a pilot cohort study in which
healthy UK adults are screened online (www.predictpd.com)
with a questionnaire that ascertains the presence of early
phenotypic features and risk factors, based on systematic
review.2 Subjects are ascribed risk scores according to their
answers and then complete additional online tests.3 Higher-
risk and lower-risk subjects are compared by using various
markers for PD and eventual clinical outcome. We hypothe-
sized that if risk stratification were effective in 1,319 eligible
participants, an excess of GBA variants and LRRK2 muta-
tions would be found in higher-risk subjects compared with
lower-risk (inclusion and exclusion criteria and risk scoring
have been previously described3). A greater likelihood of
identifying differences in outcomes was anticipated if
extremes of risk were sampled. Risk scores were ranked to
enable comparative analyses between subjects with the high-
est 15% and lowest 15% risk scores. Invitations were
extended to these subjects, and additional subjects sampled
randomly from the middle-risk group, to participate with in-
person clinical studies (see Supplemental Data Table for
sampling and acceptance rates).
Sanger sequencing was performed on DNA extracted from
the saliva of 192 subjects to screen exon 41 of LRRK2
(which contains the commonest c.6055 G>A; p.G2019S
mutation) and exons 8-11 of the GBA gene (contains almost
90% of recognized GBA pathogenic variants).4 GBA var-
iants were found in 6 of 75 higher- (1 N370S, 2 E326K, 3
T369M), 0 of 43 middle-, and 1 of 67 lower-risk subjects
(T369M homozygous) (see Table 1). The odds ratio of hav-
ing a GBA variant in the higher- versus the pooled middle-
and lower-risk groups was 9.48 (95% confidence interval,
1.12-80.47; P50.018). LRRK2 G2019S mutations were not
found in any participant.
Of the variants identified, N370S has a deleterious effect
on glucocerebrosidase enzyme activity and is known to
cause Gaucher’s disease, as well as being a clear risk factor
for PD. E326K and T369M are functionally mild variants,
not severe enough to cause Gaucher’s disease even when
present in the homozygous/compound heterozygous state.5,6
Nonetheless, our results add to the notion that both
E326K and T369M may, in the right milieu of genetic and
environmental factors, contribute to the risk of PD.4,5 Fail-
ure to find LRRK2 mutations was unsurprising given the
rarity of the G2019S mutation in healthy controls and its
presence in only 1% to 2% of patients with PD.7 GBA
variants were found in 8% of higher-risk subjects, a pro-
portion similar to estimates of frequency in sporadic PD.4
Conversely, less than 1% of lower-risk subjects were found
to have a GBA variant. An overall rate of 3.6% in the
total sample was observed, which is similar to the 4%
reported in healthy controls.5 Age is a powerful determi-
nant of PD risk but has the potential to confound given its
effect on many outcome measures used in predictive studies
(eg, sense of smell, objective motor function, and functional
imaging). By using GBA variants as an outcome for risk
stratification, age-independent support for enrichment was
observed.
Alastair J. Noyce, MRCP,†1,2 Niccolo E. Mencacci, MD,†2
Anette Schrag, FRCP, PhD,3 Jonathan P. Bestwick, MSc,4
TABLE 1. Participants, proportion tested, and mutations in
groups
Higher-Risk
Participants
Middle-Risk
Participants
Lower-Risk
Participants P-Value
Total subjects
per group
195 926 198
Number that
underwent
screening
79 45 68
Sequencing
failures
4 2 1
Sequenced
(% of total group)
75 (38) 43 (5) 67 (34)
GBA variants 6 0 1 0.018a
LRRK2 G2019S
mutations
0 0 0 -
aFisher’s exact test.
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Adaptive Deep Brain
Stimulation in a Freely
Moving Parkinsonian
Patient
The future of deep brain stimulation (DBS) for Parkinson’s
disease (PD) lies in new closed-loop systems that continuously
supply the implanted stimulator with new settings obtained
by analyzing a feedback signal related to the patient’s current
clinical condition.1 The most suitable feedback for PD is sub-
thalamic local field potential (LFP) activity recorded from the
stimulating electrode itself.2-4 This closed-loop technology
known as adaptive DBS (aDBS) recently proved superior to
conventional open-loop DBS (cDBS) in patients with PD.2
No studies have yet tested aDBS in freely moving humans
for a prolonged time. This information is an essential prereq-
uisite for developing new implantable aDBS devices for
chronic PD treatment.
In this single-case study, we tested whether a portable
DBS device we developed is suitable to compare the clinical
benefit in a freely moving PD patient induced by either
aDBS or cDBS. To do so, after a first experimental session
for extracting patient settings to personalize the aDBS algo-
rithm, we treated a blinded patient (51 y old, male, 8 y PD
history) with cDBS and aDBS in two separate experimental
sessions each lasting 120 min, 5 and 6 d, respectively, after
DBS electrode implant. To ensure reliable results, the patient
underwent repeated clinical assessments every 20 min (T1-
T5) by two independent blinded neurologists through Uni-
fied Parkinson’s Disease Rating Scale (UPDRS) III subsec-
tions and Rush Dyskinesia Rating Scale (see Supplemental
Data for details).
The aDBS portable device we used was equipped with an ad
hoc algorithm that analyzed patient’s LFP beta band power
(13-17 Hz) and adapted voltage stimulation linearly each sec-
ond (Fig. 1A).
The patient during aDBS experienced a more stable con-
dition than during cDBS, with better control of symptoms
and dyskinesias over time (Fig. 1; video 1). In particular,
aDBS and cDBS improved patient’s axial symptoms to a
similar extent (Fig. 1B), but compared with cDBS, aDBS sig-
nificantly improved his main symptom, bradykinesia
(Fig. 1C). aDBS did not elicit side effects and was well
tolerated.
Because we evaluated the patient a few days after surgery
when he probably manifested a stunning effect,5 the aDBS-
and cDBS-induced improvements were lower than those
reported by others in follow-up DBS studies.6 A major clini-
cal achievement was that compared with cDBS, aDBS
greatly reduced the patient’s dyskinesias during gait and at
rest (Fig. 1B; Fig. 1D). Presumably it did so because we
designed the adaptive algorithm to avoid dyskinesias related
to hyperstimulation: when L-dopa reduced beta-band LFP
activity, the voltage linearly diminished, avoiding
hyperstimulation.
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